AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 1, 2010, Pages 80-90

  Burashnikov, Alexander ^a   Zygmunt, Andrew C ^a   Di Diego, Jose M ^a   Linhardt, Gunilla ^b   Carlsson, Leif ^b   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

arrhythmia; electrophysiology; pharmacology; potassium channel blocker; sodium channel blocker

Indexed keywords

ACETYLCHOLINE; ANTIARRHYTHMIC AGENT; AZD 1305; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; AZABICYCLO DERIVATIVE; CARBAMIC ACID DERIVATIVE; TERT-BUTYL (2-(7-(2-(4-CYANO-2-FLUOROPHENOXY)ETHYL)-9-OXA-3,7-DIAZABICYCLO(3.3.1)NON3-YL)ETHYL)CARBAMATE;

ACTION POTENTIAL; ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIASTOLE; DOG; DRUG EFFICACY; FEMALE; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART CONDUCTION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SODIUM CURRENT; ANIMAL; ATRIAL FIBRILLATION; DISEASE MODEL; DRUG EFFECTS; ELECTROPHYSIOLOGY; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY;

ACETYLCHOLINE; ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; AZABICYCLO COMPOUNDS; CARBAMATES; DISEASE MODELS, ANIMAL; DOGS; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; HEART ATRIA; HEART VENTRICLES; MALE; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; SODIUM CHANNEL BLOCKERS;

EID: 77955229586     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181e0bc6b     Document Type: Article

References (28)

1. Yue L, Feng J, Li GR, et al. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol. 1996;496:647-662.
2. SpinelliW, Parsons RW, Colatsky TJ. Effects ofWAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol. J Cardiovasc Pharmacol. 1992;20:913-922.
3. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449-1457.
4. Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther. 1998;285: 135-142.
5. Burashnikov A, Di Diego JM, Sicouri S, et al. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm. 2008;5:1735-1742.
6. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs. 2007;16:519-532.
7. Persson F, Carlsson L, Duker G, et al. Blocking characteristics of hKv1.5 and hKv4.3/hKChIP2.2 after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Pharmacol. 2005;46:7-17. (Pubitemid 40917773)
8. Gogelein H, Brendel J, Steinmeyer K, et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:183-192.
9. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs. 2009;14: 233-249.
10. Carlsson L, Andersson B, Linhardt G, et al. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. J Cardiovasc Pharmacol. 2009; 54:82-89.
11. Goldstein RN, Khrestian C, Carlsson L, et al. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol. 2004;15:1444-1450.
12. Lofberg L, Jacobson I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace. 2006;8:549-557.
13. Crijns HJ, Van Gelder IC, Walfridsson H, et al. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006;3:1321-1331.
14. Geller JC, Egstrup K, Kulakowski P, et al. Rapid conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. J Clin Pharmacol. 2009;49:312-322.
15. Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol. 2006;47:123-132.
16. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov. 2006;5:1034-1049.
17. Burashnikov A, Antzelevitch C. New pharmacological strategies for the treatment of atrial fibrillation. Ann Noninvasive Electrocardiol. 2009;14: 290-300.
18. Persson F, Carlsson L, Duker G, et al. Blocking characteristics of hNav1.5, and hKvLQT1/hminK after administration of the novel antiarrhythmic compound AZD1309. J Cardiovasc Electrophysiol. 2005;16:329-341. (Pubitemid 40404601)
19. Burashnikov A, Mannava S, Antzelevitch C. Transmembrane action potential heterogeneity in the canine isolated arterially-perfused atrium: effect of IKr and Ito/IKur block. Am J Physiol. 2004;286:H2393-H2400.
20. Wettwer E, Hala O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation. 2004;110:2299-2306.
21. Wiesfeld AC, De Langen CD, Crijns HJ, et al. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig. J Cardiovasc Pharmacol. 1996;27:594-600.
22. Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm. 2008;5:1304-1309.
23. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999;10:1124-1152.
24. Burashnikov A, Antzelevitch C. Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol. 2006;29:290-295.
25. Andersson B, Abi-Gerges N, Carlsson L. The combined ion channel blocker AZD1305 attenuates late Na current and IKr-induced action potential prolongation and repolarization instability. Europace. 2010. In press.
26. Burashnikov A, Antzelevitch C. Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol. 2008;52:121-128.
27. Li GR, Lau CP, Shrier A. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. J Mol Cell Cardiol. 2002;34:1185-1194.
28. Zygmunt AC, Nesterenko VV, Rajamani S, et al. Mechanism of the preferential block of the atrial sodium current by ranolazine [abstract]. Biophys J. 2009;96:250a.